| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 20, 2005
Accepted on September 27, 2005
Department of Pediatrics, University of Bonn, Germany; Division of Neurosciences, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, USA; Vestische Children Hospital Datteln, University of Witten/Herdecke, Germany
* To whom correspondence should be addressed. E-mail: croth{at}uni-bonn.de.
Context: The gut hormone peptide YY3-36 (PYY) reduces food intake via hypothalamic Y2 receptors in the brain. There is not much known about PYY in obese children.
Objective: To investigate the role of PYY in the metabolic changes of obese children and its change in weight loss.
Setting: University Medical Center.
Participants: 73 obese children and 45 age-matched normal weight children.
Interventions: We determined fasting serum total PYY and leptin by RIA in obese and normal weight children. Fasting PYY was also measured in 28 obese children before and after completion of a 1-year outpatient weight reduction program.
Main outcome measures: PYY, insulin, BMI.
Results: Obese children demonstrated significantly lower PYY levels vs. lean children (median 67pg/ml vs. 124pg/ml, P < 0.001). Fasting PYY correlated negatively to the degree of overweight. PYY levels did not differ significantly between boys and girls, nor between prepubertal and pubertal children. The group of patients participating in the outpatient weight reduction program was divided into four quartiles according to their changes in SDS-BMI over a 1-year period. PYY increased significantly in patients with the most effective weight loss, but decreased in the subgroup of children with weight gain.
Conclusions: PYY is negatively correlated to the degree of overweight with reduced values in obese compared with normal weight children. Decreased PYY levels could predispose subjects to develop obesity. Our results indicate low pretreatment PYY levels that increase during weight loss may be a predictor of maintained weight loss.
This article has been cited by other articles:
 |
|
 |
|
  V. Hainer, H. Toplak, and A. Mitrakou Treatment Modalities of Obesity: What fits whom? Diabetes Care, February 1, 2008; 31(Supplement_2): S269 - S277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J Moran, M. Noakes, P. M Clifton, G. A Wittert, C. W Le Roux, M. A Ghatei, S. R Bloom, and R. J Norman Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1603 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. van den Hoek, A. C. Heijboer, P. J. Voshol, L. M. Havekes, J. A. Romijn, E. P. M. Corssmit, and H. Pijl Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E238 - E245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Chanoine Individual Differences in the Hormonal Control of Appetite: A Step toward a (More) Successful Treatment of Childhood Overweight? J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2864 - 2866. [Full Text] [PDF]
|
|
|
|
|
|
R. Morinigo, V. Moize, M. Musri, A. M. Lacy, S. Navarro, J. L. Marin, S. Delgado, R. Casamitjana, and J. Vidal Glucagon-Like Peptide-1, Peptide YY, Hunger, and Satiety after Gastric Bypass Surgery in Morbidly Obese Subjects J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1735 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. B. Chaudhri, B. C. T. Field, and S. R. Bloom From gut to mind--hormonal satiety signals and anorexia nervosa. J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 797 - 798. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
